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Abstract Patients at young age (≤35 years) diagnosed with
breast cancer (BC) are considered to have poor prognosis.
The aim of the present study was to retrospectively analyse
clinicopathological characteristics and prognosis in a group
of young BC patients. We included women diagnosed with
invasive breast carcinoma younger than/or at the age of
35 years. Between 1999 and 2009, 107 women with early-
onset BC were selected from the database of the 2nd De-
partment of Pathology at Semmelweis University. For clin-
icopathological comparison, 55 women (36–45 years), 214
women (46–65 years), 110 women (66–75 years) and 58
women (76≤years) were also included in the analysis. Fam-
ily history, clinicopathological and follow-up data were
analysed. The tissue specimens were reviewed for histolog-
ical type, nuclear grade, and estrogen receptor (ER), proges-
terone receptor (PgR), Ki67 and HER2 status (IHC4). The
mean age in the study group was 31.6 years at the time of
diagnosis. Histology showed a high incidence of grade III
tumours in this group of patients (67.9 %), while only four
cases (3.8 %) were considered grade I. According to the
immunohistochemical results, 35.3 % of the study cases
were considered as Luminal B (LumB: either being higly
proliferative or co-expressing HER2) and 33.3 % as triple
negative breast carcinomas (TNBC). The detailed question-
naire related to family history was completed and received
in 49/107 cases (45.8 %). Analysis of these data revealed an
affected family history of breast or ovarian carcinoma in
first and second degree relatives in 51.0 %. A high propor-
tion (52.0 %) of TNBC was observed among young women
with a family history of the disease. Survival analysis of the
107 patients showed that 25 (23.3 %) women died until 31
December 2012. No significant difference in survival was
detectable considering the regimen of systemic treatment
(p=0.188). Regarding clinicopathological parameters, the
immunophenotypes, grade, pT and pN values differred sub-
stantially between the age groups (p=0.001, for all), and the
shortest relapse-free survival was seen among the youngest
BC patients. This analysis illustrates that breast cancer aris-
ing in young women is characterized by the presence of less
favorable subtypes such as LumB and TNBC. The increased
proportion of TNBC was especially remarquable in the
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group of patients presenting with family history of the
disease. The fact that a high rate of death occured and no
significant difference in OS were notable regarding the
scheme of systemic therapies (neoadjuvant vs. adjuvant)
highlight the necessity of the development of new treatment
strategies.
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Introduction
Breast cancer is one of the most common cause of cancer-
related death among women worldwide. According to the
Hungarian National Cancer Registry (GRID), 6807 women
were diagnosed with breast cancer in 2007 [1]. Although,
breast cancer is relatively uncommon in young women it is
considered to be the most frequent cancer in women<40. It
is generally accepted that up to 4 % of breast cancer cases
occur in women younger than 35 years [2, 3]. In many
studies age younger than 35 years is considered as an
independent predictor of poor outcome and patients <35–
40 years at the time of diagnosis have been found to have a
poorer prognosis compared with older patients, furthermore,
multiple data have demonstrated that younger patients treat-
ed with breast carcinomas have a significantly higher rate of
local recurrence compared with older patients [4, 5]. The
group of Hanna et al. found that young women with breast
carcinomas have a higher risk of dying of the disease as
compared to middle-aged breast cancer patients even if
carcinomas are diagnosed early and patients receive state-
of-the-art treatment [5]. These results could partly be
explained by the fact that young women are diagnosed more
often at advanced stages, present unfavorable tumour char-
acteristics or have a family history of breast cancer [6–9]. In
a very recent study of Lin et al. it is suggested that these
cancers occurring at a very young age may be considered as
a distinct disease entity [10]. Due to the relatively low
frequency of breast carcinomas in women aged ≤35 years
there are few data on how risk factors predict breast cancer
in younger women and the prognostic factors in this group
have yet to be established. A proportion of breast carcinoma
arising at young age are the so called pregnancy associated
breast carcinomas (PABC). The incidence of breast cancer
in pregnancy appears higher than previously reported with
women over 35 being at greater risk [11]. In certain families
it is clear that there is a predisposition to develop breast
cancer inherited in an autosomal dominant way [12]. Previ-
ous studies have established that family history of the dis-
ease along with atypical ductal hyperplasia, or atypical
lobular hyperplasia and carcinoma in situ (DCIS or LCIS)
are important predictors of breast cancer risk [12]. The same
study found that for women ≤35 years a significant family
history of breast cancer may be a stronger predictor for
breast cancer development than the high risk lesions men-
tioned above [12]. The role of mutations in the tumour
suppressor genes BRCA1 and BRCA2 has been extensively
studied and it is considered that women who are carriers of
these mutations present a high risk of developing breast
cancer by the age of 50 [13, 14]. Although, testing for
BRCA1 and BRCA2 mutations is expensive, analysis of
these genes has important implications for the clinical man-
agement of people carrying these mutations. Several
algorythms that predict the likelihood of carrying BRCA1
and BRCA2 mutations are being currently used in clinical
practice [15–17].
According to pathological parameters, young women are
more likely to have high grade hormone receptor negative
tumours with a high proliferation rate and lymphovascular
invasion [9, 18, 19]. In the study of Lin et al. it is presented
that for women ≤35 years high Ki67 expression, TP53
mutations, ER negative status and HER2 overexpression
were associated with shorter overall survival, and TP53
mutations, Ki67, HER2 overexpression are strong prognos-
tic factors for these women [10].
The aim of the present study was to retrospectively
evaluate clinicopathological characteristics and prognosis
in a selected group of young Hungarian breast cancer pa-
tients ≤35 years.
Patients and Methods
Study Group
In our study we included patients younger than or at the age
of 35 diagnosed with invasive breast carcinoma (group nr.
1). During the period between 1999 and 2009 107 women
met these criteria altogether from the files of the 2nd De-
partment of Pathology, Semmelweis University, Budapest,
Hungary. Slides and blocks were identified from each of
these patients, and clinicopathological and follow-up infor-
mation were obtained. For comparison, 55 women (36–
45 years) (group nr. 2), 214 women (46–65 years) (group
nr. 3), 110 women (66–75 years) (group nr. 4) and 58
women (76≤years) (group nr. 5) diagnosed with breast
cancer were also included in the clinicopathological analy-
sis. Those cases, which were screen-detected breast cancers
were excluded from the study.
Pathological Evaluation
Specimens were reviewed for histological type, nuclear
grade and were stained for ER, PgR, Ki67, HER2 immuno-
histochemistry (IHC), as described further on and presented
in Table 1. Histological grading was performed according to
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the Nottingham grading system. Proxies of the molecular
subtypes were determined by immunohistochemical stains
of ER, PgR, HER2, Ki67 and HER2 FISH.
Immunohistochemical reactions (IHC) were performed
with automated immunostainer system (Ventana ES, Ventana
Medical Systems, Inc., Tucson, AZ, USA) according to
the manufacturer’s instructions using the antibodies given
in Table 1. The immunohistochemical slides were evalu-
ated by two investigators independently (JK and LM).
ER and PgR statuses were given according to the Allred
scoring system, Ki67 positivity was measured as the ratio
of positive tumour cell nuclei in the tumour and HER2
IHC was evaluated according to the guidelines, on a 0–3
scale standard protocol.
Fluorescent in situ hybridization (FISH) evaluation was
performed by using HER2/CE17 Poseidon probes (KBI-
10735, Kreatech Diagnostics, Amsterdam, The Nether-
lands). FISH results were evaluated according to the stan-
dard protocol: non-amplified if the HER2/CE17 ratio was
less than 1.8, equivocal if this ratio was between 1.8 and 2.2,
and amplified if the HER2/CE17 ratio was over 2.2. When
discordant with HER2 IHC, the FISH results were taken into
consideration.
ER and/or PgR expressing tumours with lower than 20 %
Ki67 expression were considered luminal A (LumA). For
ER and/or PgR and HER2 positive tumours and ER and/or
PgR expressing tumours with more than or equal to 20 %
Ki67 index, luminal B subtype (LumB) was assigned. Triple
negative breast cancers (TNBC) were ER, PgR, HER2 neg-
ative. The HER2 overexpressing (3+ by IHC) or 2+ cases
showing HER2 gene amplification by FISH and in the same
time ER and PgR negative tumours were considered as the
HER2+ subgroup.
Family History
A detailed questionnaire was composed and sent to the
young breast cancer patients/affected families.
Statistical Analysis
The differences between the groups were analysed using
chi-square test and the Kruskal-Wallis test with subsequent
post-hoc method. Relapse-free survival analyses were
performed using the Kaplan-Meier method. Overall survival
was determined as the time period from initial diagnosis to
the time of death. The comparison between survival func-
tions for different strata was assessed with the log-rank test.
Statistical significance was confirmed when p values were<
0.05. Statistical analysis was performed using Statistica 9.0
software (StatSoft, Tulsa, OK, USA) and SPSS 17 (SPSS
Inc., Chicago, IL, USA).
Results
Clinicopathological Assessment Median age at the time of
diagnosis in the early-onset age group was 31.64 years,
the youngest patient being diagnosed with breast carci-
noma at the age of 22. Histology showed a high inci-
dence of grade III tumours in this group of patients (70
cases, 67.96 %), while only four cases (3.88 %) were
considered grade I. In 29 cases (28.16 %) grade II cancer
was diagnosed whereas in four cases (3.73 %) we have
no data (cytology specimens only). According to the
immunophenotypical results, which were available in 99
patients, 22 tumours were enrolled in LumA (22.22 %),
35 in LumB (35.35 %), 9 in HER2+ (9.09 %) and 33 in
TNBC (33.33 %) subgroups.
The respective groups had a mean age at time of diagno-
sis as follows, 36–45 years: 41.95, 46–65 years: 54.53, 66–
75 years: 70.09 and over 76 years: 80.66. We have com-
pared the tumour characteristics of the women included in
the study, shown in Table 2. Significant difference was
detected in the comparison of the subtypes and grades
between the early-onset breast tumours and the other age
groups (p<0.001 for all, Figs. 1 and 2, respectively). Path-
ological “T” and “N” status also differed but tumour size
measured in mm’s was similar in the overall population
(Supplementary Figure 1).
Family History The detailed questionnaire related to family
history was completed and received in 49 cases (45.79 %).
Analysis of these data revealed positive family history of
breast or ovarian carcinoma reported in first and second
degree relatives in 25 cases (51.02 %). In 13 cases
(26.53 %) no family history of breast or ovarian carcinoma
was mentioned, whereas in 11 cases (22.44 %) other types
of tumours were mentioned in first and second degree rela-
tives. By accepting that the number of cases analysed is low,
interesting results were found when comparing the group of
patients with family history with the group of patients with-
out family history of breast or ovarian carcinomas. An
increased proportion (52 %) of TNBC was observed among
younger women with a family history of the disease whereas
in the group of patients without family history of breast and
Table 1 Source and dilutions of the four immunohistochemical
markers analysed in this study
Antigen Distributor, clone, dilution
ER Novocastra, 6F11 (1:200)
PgR Novocastra, 312 (1:200)
HER2 Novocastra, CB11 (1:150)
Ki-67 DAKO, MIB1 (1:100)
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Table 2 Tumour characteristics
of the 544 women included in
the study
Age group 1 2 3 4 5 p
(chi-sq.)
Number of cases 107 55 214 110 58
Subtype LUMA 22.22 % 70.00 % 70.90 % 73.33 % 66.67 % 0.001
LUMB_Pr 20.20 % 7.50 % 6.72 % 5.33 % 9.52 %
LUMB_H2 15.15 % 5.00 % 5.97 % 2.67 % 4.76 %
HER2 9.09 % 10.00 % 4.48 % 8.00 % 2.38 %
TNBC 33.33 % 7.50 % 11.94 % 10.67 % 16.67 %
Grade 1 3.88 % 29.41 % 32.61 % 32.65 % 37.74 % 0.001
2 28.16 % 35.29 % 44.57 % 39.80 % 41.51 %
3 67.96 % 35.29 % 22.83 % 27.55 % 20.75 %
T 1 31.91 % 10.74 % 11.62 % 13.52 % 11.61 % 0.001
2 39.36 % 27.52 % 29.33 % 27.05 % 27.10 %
3 2.13 % 30.20 % 29.52 % 28.11 % 28.39 %
4 1.06 % 30.20 % 28.95 % 29.89 % 29.68 %
y0 5.32 % 0.00 % 0.00 % 0.00 % 0.00 %
y1 8.51 % 0.00 % 0.00 % 0.00 % 0.00 %
y2 6.38 % 0.00 % 0.00 % 0.00 % 0.00 %
y3 4.26 % 0.00 % 0.00 % 0.00 % 0.00 %
N 0 25.58 % 41.46 % 44.72 % 44.83 % 43.48 % 0.001
1 27.91 % 51.22 % 51.22 % 46.55 % 52.17 %
2 15.12 % 7.32 % 4.07 % 8.62 % 4.35 %
3 3.49 % 0.00 % 0.00 % 0.00 % 0.00 %
y0 13.95 % 0.00 % 0.00 % 0.00 % 0.00 %
y1 6.98 % 0.00 % 0.00 % 0.00 % 0.00 %
y2 4.65 % 0.00 % 0.00 % 0.00 % 0.00 %
y3 2.33 % 0.00 % 0.00 % 0.00 % 0.00 %
Fig. 1 Differences between the subtypes in the early-onset breast
tumours and the other age groups
Fig. 2 Differences between the grades in the early-onset breast tu-
mours and the other age groups
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ovarian carcinoma the LumA tumours were found in higher
percentage (46.15 %).
Survival Analysis To assess the prognosis of all the age
groups, the relapse-free survival using Kaplan-Meier analy-
sis of the above mentioned 544 breast cancer patients was
performed. The early-onset groups displayed the worse
prognosis when compared to others (Fig. 3).
As of December 2012, 25 out of 107 (23.36 %) women
in the young BC population died. Accepting that the num-
ber of cases with known family history was relatively low,
we did not find significant association (p=0.975) between
OS and negative family history versus a family history of
breast or ovarian carcinoma in first and second degree
relatives (Fig. 4a). No statistically significant differences
were observed (p=0.188) when comparing OS in patients
with negative family history and patients having a family
history of other types of tumours (Fig. 4b). No significant
differences in survival (p=0.188) were detectable between
the applied (neoadjuvant vs. adjuvant) chemotherapy
(Fig. 4c).
When analysing the subtype of tumours in the group of
patients who died (25 pts) we found that the highest number
of deaths was observed in the LumB subgroup (36 %),
followed by the TNBC subtypes (32 %), LumA types
(20 %) and HER2+ cases (12 %).
Treatment data for the early onset breast cancer patients
included in this study was available in 56 cases. Of these
cases 24 patients (22.42 %) received neoadjuvant therapy
whereas 32 patients (29.90 %) received adjuvant therapy. In
51 cases (47.66 %) no treatment data was available. No
significant differences in survival were detectable between
the therapeutic strategies, although there was a tendency
showing benefit for neoadjuvant therapy.
In 15 cases, PABC was diagnosed. No significant differ-
ences were detected in OS when comparing the PABC with
the other group of young patients (Fig. 4d).
Discussion
According to literature data, younger patients affected by
breast carcinoma have poor outcome [6, 20, 21]. There are
increasing efforts to identify the group of patients consid-
ered high risk with higher specificity and sensitivity and
there are serious debates regarding the factors responsible
for breast cancer development at young age.
Breast cancer risk in females is increased in case of
having either a first degree relative with breast or ovarian
carcinoma, or having more than one relative affected by this
disease [22, 23]. The Cancer Collaborative Group on Hor-
monal Factors in Breast Cancer (CGoHFiB) has estimated
the cumulative incidence of breast cancer up to the age of 80
for patients with various numbers of first degree relatives
with the following cumulative incidence results: 7.8 % for
patients with no affected family, 13.3 % with one first
degree relative and 21.1 % for patients with two first degree
relatives [23].
In our study, by analysing the cases where the family
history was reported we found that in 51.02 % of the cases a
family history of breast or ovarian carcinoma was reported
in first and second degree relatives. This high prevalence of
positive family history of breast and ovarian carcinoma
highlights a considerable contribution of genetic factors to
early-onset breast cancer. Similar results were described by
Loman et al. in 2001 by analysing family history of breast
and ovarian cancers in the Swedish population. They found
that almost half of the women with early-onset breast cancer
had a family history of breast or ovarian cancer. They also
found that 9 % of early-onset breast cancer cases are asso-
ciated with germline mutation in the BRCA1 or BRCA2
genes [24].
Recent results of Evans et al. showed that few mutations
were found in young women (< 35) without family history,
demonstrating the importance of accurate documentation of
the affected family members. Their study also pointed out
that among sporadic breast cancer patients mutations are
generally present in grade III cases and TNBCs [25].
In our study we found a high incidence of grade III
tumours, while only four cases were considered as grade I
tumour. According to the immunophenotypical results,
which were available in 99 patients, 22 tumours were en-
rolled in LumA (22.22 %), 35 in LumB (35.35 %), 9 in
HER2+ (9.09 %) and 33 in TNBC (33.33 %) subgroups.
Fig. 3 The early-onset group displayed the worse prognosis when
compared with the other groups
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Patients with family history of breast or ovarian carcinomas
were represented by increased proportion (52 %) among
TNBC breast carcinoma cases when compared with the group
of patients without family history of breast and ovarian carci-
noma where the LumA tumours were found in higher per-
centage (46.15 %). In a very recent study by Jiang et al. by
analysing a heterogenous population diagnosed with breast
carcinomas it was found that in cancers diagnosed before the
age of 50, women with a family history of breast cancer are
more likely to have ER negative and PgR negative tumours
compared to women without family history [26]. This infor-
mation highlights the necessity of more detailed analyses of
the family history especially in patients of younger age.
In 2011, van der Hage et al. found that for young patients,
molecular subtype, tumour size and nodal status were inde-
pendent prognostic factors for overall survival. They also
mentioned that in their group consisting of 341 node-
negative patients, patients with LumA tumours under 40 years
of age had an overall survival rate of 94 % at 10 years
compared with patients presenting basal-like tumours with
only 72 % survival rate [27]. Another recent study found that
breast cancer in younger women (less than 40 years of age)
has distinct histopathological characteristics, but the authors
did not find reduced survival in the younger patient group as
compared with the group consisting of patients over 40 [28]. It
is controversial how this differences present between breast
carcinomas arising at the extremes age are explained. Anders
et al. suggest that these differences are strongly influenced by
genes associated with intrinsic breast cancer subtype and
grade both of which beeing correlated with age[29]. In an
earlier study of Anders et al. it is presented that breast cancer
arising in young women clearly represents a distinct biologic
entity and is characterized by specific signaling pathway[30].
In our study, at the time of analysis 23.36 % of young BC
patients died. An approximately similar high percentage of
deaths was reported by van der Hage et al. in their study
group consisting of patients less than 40 years of age [27].
The Korean Breast Cancer Society reported that young age
was associated with a greater probability of death in breast
cancer patients [31]. Upon analysing tumour subtypes in the
group of patients who died we found that of the 25 patients,
the highest number of deaths was observed in the LumB
subgroup, followed by the TNBC subgroup, LumA sub-
group and HER2+ subgroup.
We did not find significant association between OS
and negative family history versus a family history of
breast or ovarian carcinoma in first and second degree
relatives. No significant differences in OS were detectable
between the applied (neoadjuvant and adjuvant chemotherapy)
regimens either.
The results presented in this study provide further negative
data about breast cancer survival in relation to young age. We
have found that breast cancer arising in young women is
characterised by the presence of less favorable subtypes such
Fig. 4 No significant
association between OS and
negative family history versus a
family history of breast or
ovarian carcinoma in first and
second degree relatives was
detected (a). Survival of young
breast cancer patients with
negative family history versus
positive family history of any
tumour type other than breast
carcinoma (p=0.188) (b). No
significant differences in
survival (p=0.188) were
detectable between the applied
therapies (neoadjuvant
chemotherapy or adjuvant
chemotherapy), although there
was a tendency showing benefit
of neoadjuvant therapy (c). No
significant differences were
detected in OS when comparing
the PABC with the other group
of young patients (d)
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TNBC and LumB. The increased proportion of TNBC was
especially remarquable in the group of patients with a family
history of the disease. The fact that a high rate of death
occured irrespective of the applied therapies used suggests
that new and more specific treatment guidelines should be
developed in this patient group.
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